ACR Convergence 2025

Publication

ACR •
29 October, 2025 •
•

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

David B. Beck, Mael Heiblig, Sinisa Savic, Marcela A. Ferrada, Arsene Mekinian, Onima Chowdhury, Danielle Hammond, Lachelle D. Weeks, Carmelo Gurnari, Yohei Kirino , Sophie Georgin-Lavialle, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster

Available materials

Oral Presentation

Publication

ACR •
28 October, 2025 •
•

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD): Analysis of a US National Administrative Claims Database

Michael Marrone, Christopher McPherson, Abiola Oladapo

Available materials

Poster

Publication

ACR •
28 October, 2025 •
•

Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials

Puja Khanna, Amar Majjhoo, Rehan Azeem, Ben Peace, Bhavisha Desai, Vibeke Strand

Available materials

Oral Presentation

Publication

ACR •
28 October, 2025 •
•

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials

Herbert Baraf, Andrew Sulich, Guillermo Valenzuela, Rehan Azeem, Ben Peace, Bhavisha Desai, Herbert Baraf

Available materials

Poster

Publication

ACR •
28 October, 2025 •
•

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results From the Phase 3 DISSOLVE Studies

Angelo Gaffo, Herbert Baraf, Anand Patel, Tuhina Neogi, Rehan Azeem, Wesley DeHaan, Ben Peace, Hugues Santin-Janin, Bhavisha Desai, Naomi Schlesinger

Available materials

Oral Presentation

Publication

ACR •
28 October, 2025 •
•

Reduction in Tophi Observed in Patients With Uncontrolled Gout Treated With NASP: Results From Phase 3 DISSOLVE Studies

Herbert Baraf, Puja Khanna, Frédéric Lioté, Rehan Azeem, Wesley DeHaan, Ben Peace, Hugues Santin-Janin, Bhavisha Desai, Alan Kivitz

Available materials

Poster

Publication

ACR •
28 October, 2025 •
•

A Real-World Survey on Physicians' Perspectives of Uncontrolled Gout and Gout Management Practices

John Botson, Menaka Bhor, Nathan Meyer, Emily Goddard, Molly Edwards, Victoria Barton, Jeff Peterson

Available materials

Poster

Publication

ACR •
28 October, 2025 •
•

Management of Uncontrolled Gout Among Rheumatologists: Findings from a Medical Chart Audit

Hyon Choi, Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Kenneth Saag

Available materials

Poster

Publication

ACR •
27 October, 2025 •
•

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Available materials

Oral Presentation

Publication

ACR •
27 October, 2025 •
•

Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study

Alan Kivitz, Atul Singhal, Anand Patel, Rehan Azeem, Ben Peace, Bhavisha Desai, Herbert Baraf

Available materials

Poster

Publication

ACR •
27 October, 2025 •
•

The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians in the United States

Gordon K. Lam, Menaka Bhor, James Hawthorne, Arinola Dada, Molly Edwards, Emily Goddard, John Albert

Available materials

Poster

Publication

ACR •
27 October, 2025 •
•

Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study

Angelo Gaffo, Bhavisha Desai, Abiola Oladapo, Nana Kragh, Rebekah Zincavage, Brad Padilla, Naomi Schlesinger

Available materials

Poster

Publication

ACR •
26 October, 2025 •
•

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Edward M. Behrens, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Alexei A. Grom, Fabrizio De Benedetti

Available materials

Oral Presentation

Publication

ACR •
26 October, 2025 •
•

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

Kevin Byram, Herman Mann, Danielle Hammond, Sinisa Savic, Yohei Kirino , Carmelo Gurnari, Mael Heiblig, Thibault Comont, Arsene Mekinian, Mrinal Patnaik, Lachelle D. Weeks, Gary Ho, Onima Chowdhury, Adam Al-Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin-Lavialle, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster, David B. Beck

Available materials

Oral Presentation

Publication

ACR •
26 October, 2025 •
•

Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research

Lachelle D. Weeks, Danielle Hammond, Sinisa Savic, Mael Heiblig, Onima Chowdhury, Arsene Mekinian, Carmelo Gurnari, Radhakrishnan Ramchandren, Sophie Georgin-Lavialle, Marcela A. Ferrada, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, David B. Beck, Matthew J. Koster

Available materials

Poster

Medical materials